Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;24(4):658-669.
doi: 10.1007/s12094-022-02801-2. Epub 2022 Mar 26.

SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

Ana Fernández-Montes  1 , Julia Alcaide  2 , María Alsina  3   4 , Ana Belén Custodio  5 , Lourdes Fernández Franco  6 , Javier Gallego Plazas  7 , Carlos Gómez-Martín  8 , Paula Richart  9 , Fernando Rivera  10 , Marta Martin-Richard  11
Affiliations
Review

SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

Ana Fernández-Montes et al. Clin Transl Oncol. 2022 Apr.

Abstract

Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.

Keywords: Diagnosis; Esophageal cancer; Treatment.

PubMed Disclaimer

Conflict of interest statement

AFM reports Advisory Board and Speaker from Pierre Fabre and Astrazeneca; Speaker from Lilly, Servier, Amgen,MSDd and Seagen; Advisory Board from Bayer and Mundipharma. FRH reports Advisory Board and Speaker from Roche, BMS, Sanofi, Amgen, Merck-Serono and Lilly; Advisory Board, Speaker and- Grant from MSD, Servier and AstraZeneca. MAM reports Advisory Board and Speaker from BMS, MSD, Lilly and Servier; Speaker from Amgen and Roche. JAG reports Advisory Board from Merck; Speaker from Amgen, Roche, Bayer and Ipsen. JGP reports Advisory Board, Speaker and Other from Eli Lilly; Advisory Board and Other from BMS and Servier; Advisory Board from MSD. CGM, PR and LFF have nothing to disclose.

References

    1. OncologíaMédica Sed (2021) Las cifras del cáncer en España. https://seom.org/images/cifras del Cácner en espanha 20212021.
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
    1. Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69(9):1564–1571. - PubMed
    1. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, Brigham, Women's H, Broad I, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. - PMC - PubMed
    1. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist. 2018;23(11):1319–1327. - PMC - PubMed